Author:
Lai Yongkang,Dong Xiaoyang,Song Yingxiao,Zhao Jiulong,Du Yiqi,Li Zhaoshen
Abstract
Abstract
Background
Eradication of oral Helicobacter pylori (H. pylori) not only reduces the infection rate from the transmission route but also improves the success rate of intragastric eradication. MAXPOWER Biological Bacteriostatic Liquid, developed in our previous work, is a composite biological preparation with strong antibacterial ability and unique antibacterial mechanism. The present study evaluated the efficacy of the MAXPOWER biocontrol solution on H. pylori and its success rate in eradicating oral H. pylori in clinical patients.
Methods
Live-dead cell staining and hemolysis test were used to evaluate the cellular safety of MAXPOWER biocontrol solution; plate spreading, live-dead bacterial staining, and scanning electron microscopy methods were used to evaluate its antimicrobial effect against H. pylori. Transcriptomics was used to analyze the changes in H. pylori genes before and after treatment. After seven days of gavage treatment, H&E staining and mice feces were collected for 16SrDNA sequencing to evaluate the animals’ safety. Oral H. pylori-positive patients were randomized to be given a placebo and MAXPOWER Bio-Bacteriostatic Liquid gargle for seven days to evaluate the effect on oral H. pylori eradication.
Results
In vitro tests demonstrated that this product has excellent biocompatibility and hemocompatibility and can effectively eradicate oral H. pylori. In vivo tests further showed that it has good biosafety and virtually no adverse effect on intestinal microflora. Transcriptomics analysis revealed that it kills H. pylori cells mainly by disrupting their cell membranes and metabolism. Additionally, the results of randomized controlled trials on humans disclosed that the oral H. pylori eradication rates achieved by MAXPOWER Biological Antibacterial Liquid were 71.4% and 78.9% according to the intention-to-treat and the per-protocol analysis, respectively.
Conclusion
MAXPOWER Biological Antibacterial Liquid is both safe and efficacious in the eradication of oral H. pylori.
Trial registration
This study was retrospectively registered in the ClinicalTrials.gov Trial Registry on 21/09/2023 (NCT06045832).
Funder
Nanchang University Graduate Student Innovation Fund
Shanghai Rising-Star Programand
the Strategic Consulting Research Project of Chinese Academy of Engineering
the Project of Shanghai Municipal Health Commission
Shanghai Clinical Medical Research Center for Digestive Diseases Project
Shanghai Outstanding Academic Leaders Program
Publisher
Springer Science and Business Media LLC
Reference42 articles.
1. Malfertheiner P, Megraud F, Rokkas T, Gisbert JP, Liou JM, Schulz C et al. Management of helicobacter pylori infection: The maastricht vi/florence consensus report. Gut 2022.
2. Ding SZ, Du YQ, Lu H, Wang WH, Cheng H, Chen SY, et al. Chinese consensus report on family-based helicobacter pylori infection control and management (2021 edition). Gut. 2022;71:238–53.
3. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process–first American cancer society award lecture on cancer epidemiology and prevention. Cancer Res. 1992;52:6735–40.
4. Wang YC. Medicinal plant activity on helicobacter pylori related diseases. World J Gastroenterol. 2014;20:10368–82.
5. Du Y, Zhu H, Liu J, Li J, Chang X, Zhou L, et al. Consensus on eradication of helicobacter pylori and prevention and control of gastric cancer in China (2019, Shanghai). J Gastroenterol Hepatol. 2020;35:624–9.